Eris Lifesciences Ltd on Monday reported a 39.16 per cent rise in consolidated net profit to ₹187.14 crore in the September quarter, driven by growth in its domestic branded formulations business.
The company had posted a net profit of ₹134.47 crore in the same period of the previous fiscal year, Eris Lifesciences Ltd said in a regulatory filing.
Total revenue from operations in the second quarter was ₹892.37 crore as against ₹792.41 crore in the year-ago period, it added. Total expenses in the quarter under review stood at ₹702.86 crore as compared to ₹622.83 crore in the same period a year ago, the company said.
Eris Lifesciences Ltd Chairman & Managing Director Amit Bakshi said in a press statement, “Our domestic branded formulations business delivered 14 per cent revenue growth in Q2, with our major therapies continuing to outgrow the market. Diabetes has emerged stronger following our insulin and semaglutide launches, growing 18.5 per cent against market growth of 16.1 per cent.”
Bakshi further shared that Eris’s in-house developed recombinant Semaglutide has received approval to conduct Phase 1 and Phase 3 clinical trials.
Shares of Eris Lifesciences settled 0.37 per cent down at 1,093.60 apiece on the BSE on Monday.
Published on October 26, 2026
